Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation

European Journal of Medical Research

Volumn 12, Issue 8, 2007, Pages 337-340

  Gahn, Benedikt ^a   Schub, N ^a   Repp, R ^a   Gramatzki, M ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Bone marrow transplantation; Candidiasis; Caspofungin; Voricazole

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; AMSACRINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASPARAGINASE; CASPOFUNGIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VINCRISTINE; VINDESINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANDIDA KRUSEI; CANDIDIASIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOADING DRUG DOSE; MAINTENANCE THERAPY; MALE; MYCOSIS;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LIPOSOMES; MALE; PEPTIDES, CYCLIC; PYRIMIDINES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 34548493204     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Antoniadou A, Kontoyiannis DP. Status of combination therapy for refractory mycoses. Curr Opi Infect Dis. 2003; 16:539-545
2. Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Greganti G, Giannini D, Rinaldi MG, Scalise G. Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother. 2005 Jun;49 (6):2546-9.
3. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.: Am J Ophthalmol. 2005 Jan;139(1):135-40.
4. Di Bonaventura G, Spedicato I, Picciani C, D'Antonio D, Piccolomini R. Antimicrob Agents Chemother. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. 2004 Nov;48(11):4453-6.
5. Elouennass M, Doghmi K, Fagot T, Soler C, Mac Nab C, Foissaud V, De Revel T, Herve V. Hepatosplenic and kidneys candidasis complicating an acute myeloblastic leukemia. A case treated with voriconazole and caspofungin. Ann Biol Clin (Paris). 2005 Jul-Aug;63(4):423-7.
6. Franzot, S. P. & Casadevall A. (1997). Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother41, 331-6.
7. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343-500.
8. Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother. 2003 Jun;51(6):1427-9. Epub 2003 Apr 25.)
9. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother. 2005 Jul;6(7):1215-29
10. Kruger W, Russmann B, Kroger N, Salomon C, Ekopf N, Elsner HA, Kaulfers PM, Mack D, Fuchs N, Durken M, Kabisch H, Erttmann R, Zander AR. Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases. Bone Marrow Transplant. 1999 Mar;23(6):589-97.
11. Kruger W, Stockschlader M, Sobottka I, Betker R, De Wit M, Kroger N, Grimm J, Arland M, Fiedler W, Erttmann R, Zander AR. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation Leuk Lymphoma. 1997 Feb;24(5-6):491-9.
12. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005 Oct 22-28;366(9495):1435-42.
13. Lewejohann J, Hansen M, Zimmermann C, Muhl E, Bruch HP. Recurrent Candida sepsis with prolonged respiratory failure and severe liver dysfunction. Mycoses. 2005;48 Suppl 1:94-8.]
14. Lewis RE, Kontoyiannis DP. Rationale for combination anti-fungal therapy. Pharmacotherapy. 2001 Aug;21(8 Pt 2): 149S-164S.
15. Liu KH, Wu CJ, Chou CH, Lee HC, Lee NY, Hung ST, Ko WC. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin.: J Clin Microbiol. 2004 Dec;42(12):5950-3.
16. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004 Feb 15;103(4):1527-33. (Epub 2003 Oct 2.)
17. Maschmeyer G, Glasmacher A. Pharmacological properties and clinical efficacy of a recently licensed systemic anti-fungal, caspofungin.Mycoses. 2005 Jul;48(4):227-34.
18. DiNubile MJ, Hille D, Sable CA, Kartsonis NA. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect. 2005 Jun;50(5):443-9.).
19. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14): 2049-68.
20. Mohammedi I, Thiebaut A, Piens MA, Argaud L, Martin O, Robert D. Emergence of Candida albicans fungemia during voriconazole therapy. J Infect. 2005 Oct;51 (3):e83-4.
21. Nivoix Y, Zamfir A, Lutun P, Kara F, Remy V, Lioure B, Rigolot JC, Entz-Werle N, Letscher-Bru V, Waller J, Leveque D, Koffel JC, Beretz L, Herbrecht R. Management of systemic fungal infections: alternatives to itraconazole. J Infect. (in press).
22. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003 Oct; 47(10):3149-54.)
23. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003 Nov;22(11): 651-5).
24. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother. 2002 Jun;46(6):1723-7.
25. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003 May 15;36(10): 1221-8. (Epub 2003 May 8)
26. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, Freireich EJ, Raad II. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004 Dec 15;101 (12):2859-65.
27. Safdar A, Armstrong D. Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies. Bone Marrow Transplant. 2002A Dec;30(12):931-5.
28. Safdar A, Armstrong D, Cross EW, Perlin DS. Prospective epidemiologic analysis of triazole-resistant nosocomial Candida glabrata isolated from patients at a comprehensive cancer center. Int J Infect Dis. 2002B Sep;6(3):198-201.
29. Schafer-Korting M. New systemic antifungal drugs: mechanisms of action, drug interactions and side effects Mycoses. 2003;46 Suppl 1:28-31
30. Sims CR, Ostrosky-Zeichner L, Rex JH. Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res. 2005 Nov-Dec;36(6):660-71.
31. Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med. 2004 Mar;5(2):181-3